

---

GUERNSEY STATUTORY INSTRUMENT

---

1989-No. 32

THE MISUSE OF DRUGS (DESIGNATION)  
ORDER, 1989.

Made ..... 29 September 1989


Laid before the States .....

Coming into Operation ..... 2 October 1989

THE STATES BOARD OF HEALTH, in exercise of the powers conferred upon it by section 6(4) of the Misuse of Drugs (Bailiwick of Guernsey) Law, 1974 (a) as amended (b) hereby orders:-

1. This Order may be cited as the Misuse of Drugs (Designation) Order 1989 and shall come into operation on 2 October 1989.
2. (1) The controlled drugs specified in Part 1 of the Schedule hereto are hereby designated as drugs to which section 6 (4) of the Misuse of Drugs (Bailiwick of Guernsey) Laws 1974 to 1988 applies.  
  
(2) Part II of the Schedule hereto shall have effect for the purpose of specifying those controlled drugs which are excepted from Part I thereof.
3. The Misuse of Drugs (Designation) Order 1976 is hereby revoked.

Dated this 29<sup>th</sup> day of September 1989



J.R.R. HENRY  
President of the States Board of Health  
for and on behalf of the Board

---

(a) Ordres en Conseil Vol. XXIV, p. 273

(b) Recueil d'Ordonnances Tome XX, p. 271

SCHEDULE

Regulation two

Controlled drugs to which sub-section (4) of section six of the Misuse of Drugs (Bailiwick of Guernsey) Laws 1974 to 1988 applies.

Part I

1. The following substances and products, namely:-

- |                            |   |
|----------------------------|---|
| (a) Bufotenine             | Lysergide and other <u>N</u> -alkyl derivatives   |
| Cannabinol                 | of lysergamide                                    |
| Cannabinol derivatives     | Mescaline   |
| Cannabis                   | Psilocin  |
| Cannabis resin             | Raw opium   |
| Cathinone                  | Rolicyclidine                                     |
| Coca leaf                  | Tenocyclidine                                     |
| Concentrate of poppy-straw | 4-Bromo-2, 5-dimethoxy- $\alpha$ -                |
| Eticyclidine               | methylphenethylamine                              |
| Lysergamide                | <u>N,N</u> -Diethyltryptamine                     |
|                            | <u>N,N</u> -Dimethyltryptamine                    |
|                            | 2,5-Dimethoxy- $\alpha$ ,4-dimethylphenethylamine |

← Insertions  
[See GSI  
1991/17]

- (b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;
- (c) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, an N-alkylphenethylamine,  $\alpha$ -methylphenethylamine, an N-alkyl- $\alpha$ -methylphenethylamine,  $\alpha$ -ethylphenethylamine, or an N-alkyl- $\alpha$ -ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylendioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents;
- (d) any compound (not being a compound for the time being specified in Part II of this Schedule) structurally derived from fentanyl by modification in any of the following ways, that is to say,
- (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;

- (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
  - (iii) by substitution in the piperidine ring with alkyl, or alkenyl groups;
  - (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylendioxy, halogeno or haloalkyl groups;
  - (v) by substitution at the 4-position of the piperidine ring with any alkoxy-carbonyl or alkoxyalkyl or acyloxy group;
  - (vi) by replacement of N-propionyl group by another acyl group;
- (e) any compound (not being a compound for the time being specified in Part II of this Schedule) that is structurally derived from pethidine by modification in any of the following ways, that is to say,
- (i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
  - (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
  - (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
  - (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxy-carbonyl or any alkoxyalkyl or acyloxy group;
  - (v) by formation of an N-oxide or of a quaternary base.
2. Any stereoisomeric form of a substance specified in paragraph 1 above.
  3. Any ester or ether of a substance specified in paragraph 1 or 2 above.
  4. Any salt of a substance specified in any of paragraphs 1 to 3 above.
  5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4 above.

Part II

CONTROLLED DRUGS EXCEPTED FROM PART I

1. The compounds referred to in paragraph 1(d) of Part I of this Schedule are -

Alfentanil  
Carfentanil  
Lofentanil  
Sufentanil.

2. The compounds referred to in paragraph 1(e) of Part I of this Schedule are -

Allylprodine  
Alphameprodine  
Alphaprodine  
Anileridine  
Betameprodine  
Betaprodine  
Hydroxypethidine  
Properidine  
Trimeperidine.

EXPLANATORY NOTE

(This note is not part of the Order)

Section 6(3) of the Misuse of Drugs (Bailliwick of Guernsey) Law 1974, as amended, requires an Ordinance to be made by the States to allow the use for medical purposes of the drugs which are subject to control under that Law. Section 6(3) does not, however, apply to any drug designated by Order under Section 6(4) as a drug to which Section 6(4) is to apply.

This Order, which replaces the Misuse of Drugs (Designation) Order 1976 designates for this purpose the drugs specified in Part 1 of the Schedule to the Order. It differs from the previous Order by the addition, in paragraph 1 of Part 1, of cathinone, eticyclidine, rolicyclidine and tenocyclidine and by adding sub-paragraphs (b), (c), (d) and (e) which relate respectively to certain tryptamine derivatives, certain phenethylamine derivatives, certain fentanyl derivatives and certain pethidine derivatives.

Part II of the Schedule specifies certain compounds which are excepted from paragraph 1(d) and 1(e) of Part I and are therefore not designated by this Order.

MISUSE OF DRUGS LAWS 1974-1988

IMPORTATION AND EXPORTATION LICENCE

In pursuance of section 2(2)(b) of the Misuse of Drugs Laws 1974-1988, the Board of Health (herein after "the Board") hereby licences, with effect from 1 October, 1989 and subject to the terms and conditions specified below, the importation and exportation of -

- (a) any controlled drug specified in Part I of the Schedule to this licence by a person who is entering or leaving the Bailiwick of Guernsey (herein after "the Bailiwick") where that drug is prescribed for administration for dental or medical purposes to himself or to a member of his household who is unable to administer the drug himself and who is travelling with that person at the time of importation or exportation;
- (b) any controlled drug specified in Part II of the Schedule of this licence by a doctor of medicine who is entering or leaving the Bailiwick -
  - (i) with a patient for whose treatment during that journey to or from the Bailiwick the doctor considers the drug may be necessary;
  - (ii) for the purpose of immediately leaving, or within the next three days entering, the Bailiwick with such a patient; or
  - (iii) within three days after its lawful exportation by him when leaving, or immediately after its lawful importation by him when entering, the Bailiwick with a patient for whose treatment during that journey from or to the Bailiwick the doctor considered the drug might be necessary.


The terms and conditions attached to this licence are:-

- 1. The amount of any controlled drug import or exported under this licence shall not exceed -
  - (a) on each occasion on which it is imported or exported, the quantity specified in respect of that drug in column 2 of the Schedule to this licence;
  - (b) in any period of thirty days, twice that quantity.
- 2. This licence does not apply -
  - (a) to any controlled drug which is not contained in a medicine within the meaning of the Poisons and Pharmacy Ordinance 1970;
  - (b) unless the controlled drug is under the direct personal supervision of the person importing or exporting it;
  - (c) to the exportation of any controlled drug by a person who is not lawfully in possession of the drug.

It is hereby directed that, notwithstanding any provision in Ordinances under section 9 of the Misuse of Drugs Law with respect to record-keeping, no record is required to be kept of any quantity of controlled drug imported or exported under this licence.

The Importation and Exportation licence dated 2 February, 1989 is hereby revoked.

This licence shall remain in force until revoked by Order of the Board.



(J. R. R. Henry)  
President, States Board of Health  
for and on behalf of the Board

29<sup>th</sup> September, 1989

Board of Health  
Administration Office  
Le Vauquiedor  
St Martins  
Guernsey

SCHEDULE

PART I

Column 1	Column 2
Controlled drugs	Maximum quantity
Alphaprodine	3.6g
Amphetamine	300mg
Amphetamine Phosphate	225mg
Amphetamine Sulphate	225mg
Anhydrous Morphine	360mg
Anileridine	900mg
Anileridine Hydrochloride	900mg
Anileridine Phosphate	900mg
Benzphetamine	2.25g
Bezitramide	450mg
Buprenorphine Hydrochloride	24mg
Chlorphentermine Hydrochloride	975mg
Cocaine Hydrochloride, Nitrate or Sulphate Eyedrops	20ml at 4%L or 4ml at maximum strength
Cocaine Hydrochloride, Nitrate or Sulphate as active ingredient in a mixture being used by a patient who is terminally ill	500mg
Dexamphetamine	300mg
Dexamphetamine Phosphate	150mg
Dexamphetamine Sulphate	900mg
Dextromoramide Tartrate	900mg
Diamorphine Hydrochloride as an ingredient in a mixture or linctus	500mg
Diamorphine Hydrochloride Tablets	450mg
Diamorphine Hydrochloride Ampoules	1.35g
Diamorphine Hydrochloride Elixir	500mg
Diethylpropion Hydrochloride	1.125g
Dihydrocodeine Tartrate	3.6g
Dihydrocodeinone 0-carboxymethyloxime	150mg
Dipipanone	600mg
Drotebanol	90mg
Ethchlorvynol	15g
Ethinamate	15g
Fentanyl Citrate	45mg
Glutethimide	7.5g
Hydrocodone Hydrochloride	675mg
Hydrocodone Phosphate	675mg
Hydrocodone Tartrate	675mg
Hydromorphone	360mg
Ketobemidone	450mg
Levorphanol Tartrate	135mg
Mazindol	45mg
Mecloqualone	4.5g
Medicinal Opium	1.8g
Mephentermine Sulphate	2.7g
Meprobamate	3.6g
Methadone Hydrochloride Ampoules	500mg
Methadone Hydrochloride Linctus	500mg
Methadone Hydrochloride Tablets	500mg
Methadyl Acetate	500mg
Methaqualone	4.5g
Methaqualone Hydrochloride	4.5g
Methylamphetamine	900mg
Methylamphetamine Hydrochloride	900mg
Methylamphetamine Saccharate	900mg

Column 1 (Cont)	Column 2 (Cont)
Methylphenidate Hydrochloride	900mg
Methylphenobarbitone	9g
Methylprylone	6g
Metopon	1.35g
Morphine Hydrochloride	1.2g
Morphine Sulphate	1.2g
Morphine Tartrate	1.2g
Norpipanone Hydrochloride	270mg
Oxycodone Hydrochloride	900mg
Oxycodone Pectinate	900mg
Oxymorphone Hydrochloride	450mg
Pentazocine Hydrochloride	9g
Pentazocine Lactate	5.4g
Pethidine Hydrochloride	2.25g
Phenadoxone	2.25g
Phenazocine	450mg
Phendimetrazine Tartrate	3.2g
Phenmetrazine Hydrochloride	1.25g
Phentermine	450mg
Piminodine Esylate	4.5g
Pipradrol Hydrochloride	90mg
Piritramide	3.6g
Piritramide Hydrogen Tartrate	3.6g
Propiram Fumarate	2.25g
Thebacon Hydrochloride	225mg
Tilidate Hydrochloride	6g
Trimeperidine Hydrochloride	2.25g
The following 5, 5-disubstituted Barbituric acids:	
Allobarbitone	3g
Amylobarbitone	9g
Amylobarbitone Sodium	9g
Aprobarbitone	7.5g
Barbitone	9g
Barbitone Sodium	9g
Butalbital	6g
Butallylonal	9g
Butobarbitone	4.5g
Cyclobarbitone	6g
Cyclobarbitone Calcium	6g
Cyclopentobarbitone	3g
Heptabarbitone	6g
Hexethal Sodium	18g
Ibomal	6g
Nealbarbitone	3g
Pentobarbitone	3g
Pentobarbitone Calcium	3g
Pentobarbitone Sodium	3g
Phenobarbitone	2.7g
Phenobarbitone Sodium	12g
Phenylmethylbarbituric acid	6g
Probarbitone Sodium	22.5g
Probarbitone Calcium	22.5g
Proxibarbal	9g
Quinalbarbitone	3g
Quinalbarbitone Sodium	3g
Secbutobarbitone	1.8g
Secbutobarbitone Sodium	1.8g

---

Column 1 (Cont)	Column 2 (Cont)
Talbutal	2.25g
Vinbarbitone	3g
Vinbarbitone Sodium	3g
Vinylbitone	3g

---

PART II

Column 1	Column 2
Controlled Drug	Maximum Quantity
Anhydrous Morphine	360mg
Diamorphine Hydrochloride as an ingredient in a mixture or linctus	500mg
Diamorphine Hydrochloride Tablets	450mg
Diamorphine Hydrochloride Ampoules	1.35g
Diamorphine Hydrochloride Elixir	500mg
Morphine Sulphate	1.2g
Pethidine Hydrochloride	2.25g

MISUSE OF DRUGS LAWS 1974-1988

LICENCE TO POSSESS

In pursuance of Section 2 of the Misuse of Drugs (Bailiwick of Guernsey) Ordinances 1976 to 1989 the Board of Health hereby issues a licence, with effect from 1 October, 1989, under that Section authorising any person who imports a controlled drug under and in accordance with the Importation and Exportation licence dated 29<sup>th</sup> September, 1989 to have that drug in his possession.

The licence to possess dated 2 February, 1989 is hereby revoked.



(J. R. R. Henry)  
President, States Board of Health  
for and on behalf of the Board

29<sup>th</sup> September, 1989

Board of Health  
Administration Office  
Le Vauquiedor  
St Martins  
Guernsey

MISUSE OF DRUGS LAW 1974

"OPEN GENERAL LICENCE" FOR THE IMPORTATION AND EXPORTATION OF  
SMALL QUANTITIES OF CERTAIN CONTROLLED DRUGS

EXPLANATORY NOTE

This licence authorises the importation (and subsequent possession) and exportation of small quantities (as specified in the Schedule to the licence) of certain controlled drugs in Schedules 2 and 3 to the Misuse of Drugs Ordinance 1976 needed by patients and doctors arriving from, or departing to, anywhere outside the Bailiwick of Guernsey.

The licence will come into operation on 1 October, 1989 and will be valid until further notice.

Under the licence it will not be necessary for doctors and patients arriving in the Bailiwick to declare drugs the importation of which is authorised by the licence. As the licence has, inevitably, a certain degree of potential for abuse of the concessions it contains the drugs which may be imported and exported by any individual doctor are limited to those specified in Part II of the Schedule, with maximum amounts which may be carried at any one time and within any period of thirty days. Nurses accompanying seriously ill patients will be regarded as "members of the household" of the patient for the purposes of the licence (see introductory sub-paragraph (a) on page 1 of the licence).

The terms of the licence as they concern the controlled drug allowances for patients, should not be publicised outside medical circles. These allowances are simply intended to regularise the present situation whereby travellers with medically or dentally prescribed controlled drugs often innocently breach Bailiwick import and export controls, and unnecessary publicity for the new licence would provide scope for abuse of the new arrangements.

The original of the licence is being retained in the administration offices of the Board of Health.

Board of Health  
Le Vauquiedor  
St Martins  
Guernsey

September 1989